title: Commentary: Doxazosin for alcoholism.
abstract: Recent preclinical and clinical evidence using prazosin indicates that α(1) -blockade may represent a new approach to treat alcohol dependence (AD). While most of the alcohol research on α(1) -blockade has been conducted testing prazosin, O'Neil and colleagues recently performed a set of preclinical experiments testing another α(1) -blocker, doxazosin, which has a longer half-life that may enhance clinical utility. Doxazosin and prazosin share the same chemical structure, in which the central element is a piperazine ring. O'Neil and colleagues' main results are that doxazosin significantly reduced alcohol intake without affecting locomotor activity. As such, O'Neil and colleagues provide the first preclinical evidence of the possible role of doxazosin in AD. Additional translational research is needed to further test this hypothesis.
authors.affiliation: Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, Laboratory of Clinical and Translational Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892, USA. lorenzo.leggio@nih.gov
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Leggio
authors.forename: George A
authors.initials: GA
authors.lastname: Kenna
mesh_terms: D058668:Adrenergic alpha-1 Receptor Antagonists / Q000627:therapeutic use*; D000428:Alcohol Drinking / Q000188:drug therapy*; D000437:Alcoholism / Q000188:drug therapy*; D000818:Animals; D004195:Disease Models, Animal; D017292:Doxazosin / Q000627:therapeutic use*; D008297:Male; D051381:Rats
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D017292:Doxazosin